Press Releases

Month Year

Month Year

Investor Alerts

Mar 21, 2018

Trevi Therapeutics to Present at Needham & Company’s 17th Annual Healthcare Conference
Oct 12, 2017

Trevi Therapeutics Hires Dr. Helena Brett-Smith as Chief Development Officer
Jul 19, 2017

Trevi Therapeutics Raises $50 Million Series C Financing Led by New Enterprise Associates
Mar 7, 2017

Trevi Therapeutics Names Michael Heffernan to its Board of Directors
Nov 15, 2016

Trevi Therapeutics Selected to Present at the American Society of Nephrology's Kidney Week 2016 Phase 2/3 Data for NalbuphineER in Uremic Pruritus
Oct 12, 2016

Trevi Therapeutics Announces Positive Results from Phase 2 Trial in Prurigo Nodularis
Jun 2, 2016

Trevi Therapeutics Announces Completion of Enrollment in Phase 2/3 Study of Nalbuphine ER in Prurigo Nodularis
Apr 28, 2016

Trevi Therapeutics to Present Two Posters at the National Kidney Foundation Spring 2016 Meeting
Mar 1, 2016

Trevi Therapeutics' Data to be Presented at the American Academy of Dermatology's 74th Annual Meeting in Washington, DC
Oct 29, 2015

Trevi Therapeutics Selected to Present at the American Society of Nephrologys Kidney Week 2015 at High-Impact Clinical Trials Session with Phase 2/3 Data for Nalbuphine ER

Show per page

Media Contact

Katie McManus
(203) 903-9627
k.mcmanus@trevitherapeutics.com

Trevi Therapeutics
195 Church Street, 14th Floor
New Haven, CT 06510
map